# The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

> **NCT06092242** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The Second Affiliated Hospital of Shandong First Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Tas-102(Suyuan) combined with bevacizumab

## Key facts

- **NCT ID:** NCT06092242
- **Lead sponsor:** The Second Affiliated Hospital of Shandong First Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10-15
- **Primary completion:** 2025-10-15
- **Final completion:** 2027-10-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06092242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06092242, "The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06092242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*